Human RCT Evidence is a recurring topic in our peptide coverage. This hub collects every article tagged Human RCT Evidence, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical monograph on cagrilintide — the long-acting amylin analogue and amylin half of CagriSema. Genuine phase 3 human RCTs, ~22.7% combination weight loss, and an unapproved 2026 legal status.
A clinical monograph on Actovegin — the deproteinized calf-blood hemodialysate marketed abroad for diabetic neuropathy, post-stroke cognition and sports recovery. Two human RCTs, an ill-defined composition, and an unapproved U.S. status.
A clinical monograph on ARA-290 (cibinetide) — the non-erythropoietic EPO-derived peptide with genuine Phase 2 RCT data for small-fiber neuropathy, no Phase 3, and an unapproved, WADA-prohibited 2026 status.
A clinical monograph on Angiotensin-(1-7) / TXA127 (talfirastide) — the effector of the protective ACE2/Mas arm of the renin-angiotensin system. Real human RCTs, a negative COVID-19 trial, and no FDA approval.
A clinical monograph on alanyl-glutamine (Dipeptiven) — the stable dipeptide built to deliver glutamine intravenously. Grade-A but contested evidence in parenteral nutrition, with a major high-dose mortality signal.
A clinical monograph on abaloparatide (Tymlos) — the FDA-approved PTHrP(1-34) bone-anabolic peptide. Phase 3 RCT fracture data in women and men, RG-selective PTH1R mechanism, and 2026 regulatory status.
A clinical monograph on AOD-9604 — the hGH-fragment fat-loss peptide that completed six human RCTs and largely failed to beat placebo. Strong safety data, a failed pivotal weight-loss trial, and an unsettled 2026 legal status.
Human RCT Evidence is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Human RCT Evidence, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.